Compile Data Set for Download or QSAR
Report error Found 72 Enz. Inhib. hit(s) with all data for entry = 11846
TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652318(US20240059675, Example 21)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652363(US20240059675, Example 32)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652313(US20240059675, Example 16)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652312(US20240059675, Example 15)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652300(US20240059675, Example 4)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652363(US20240059675, Example 32)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652312(US20240059675, Example 15)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652324(US20240059675, Example 26)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652324(US20240059675, Example 26)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652310(US20240059675, Example 13)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652310(US20240059675, Example 13)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652305(US20240059675, Example 8)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652305(US20240059675, Example 8)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652326(US20240059675, Example 28)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652297(US20240059675, Example 1)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652309(US20240059675, Example 12)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652309(US20240059675, Example 12)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652316(US20240059675, Example 19)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652327(US20240059675, Example 29)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652298(US20240059675, Example 2 | US20240101544, Example ...)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652328(US20240059675, Example 30)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652328(US20240059675, Example 30)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652304(US20240059675, Example 7)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652330(US20240059675, Example 31)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652303(US20240059675, Example 6)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652301(US20240059675, Example 5)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652299(US20240059675, Example 3)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652299(US20240059675, Example 3)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652326(US20240059675, Example 28)
Affinity DataIC50: 3nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652318(US20240059675, Example 21)
Affinity DataIC50: 3nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652319(US20240059675, Example 22)
Affinity DataIC50: 3nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652330(US20240059675, Example 31)
Affinity DataIC50: 3nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652325(US20240059675, Example 27)
Affinity DataIC50: 3nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652327(US20240059675, Example 29)
Affinity DataIC50: 3nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652297(US20240059675, Example 1)
Affinity DataIC50: 4nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652306(US20240059675, Example 9 | US20240101544, Example ...)
Affinity DataIC50: 4nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652307(US20240059675, Example 10)
Affinity DataIC50: 4nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652314(US20240059675, Example 17)
Affinity DataIC50: 4nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652313(US20240059675, Example 16)
Affinity DataIC50: 4nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652325(US20240059675, Example 27)
Affinity DataIC50: 5nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652320(US20240059675, Example 23)
Affinity DataIC50: 6nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652315(US20240059675, Example 18)
Affinity DataIC50: 8nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652303(US20240059675, Example 6)
Affinity DataIC50: 8nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652307(US20240059675, Example 10)
Affinity DataIC50: 8nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652314(US20240059675, Example 17)
Affinity DataIC50: 8nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652323(US20240059675, Example 25)
Affinity DataIC50: 10nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652311(US20240059675, Example 14)
Affinity DataIC50: 10nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652316(US20240059675, Example 19)
Affinity DataIC50: 10nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652311(US20240059675, Example 14)
Affinity DataIC50: 11nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652308(US20240059675, Example 11)
Affinity DataIC50: 11nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 72 total ) | Next | Last >>
Jump to: